The Best Target & The Best Chemical
Fibroblast growth factor receptor (FGFR), a well-known oncogene, is a representative receptor tyrosine kinase (RTK) located in cell membranes. FGFR signaling is known to be involved in the development and progression of cholangiocarcinoma and bladder cancer, and after going through the first-generation inhibitors with low selectivity, the second-generation FGFR inhibitors are currently approved by the FDA and are used for bladder and cholangiocarcinoma. However, mutations resistant to FGFR inhibitors have been reported one after another, reducing the therapeutic effect. We are developing FGFR inhibitor PHI-401 using big data and AI-based platforms to overcome resistant mutations, which are the most important barriers to kinase inhibitors.
About 20% of cholangiocarcinoma
and urothelial carcinoma patients
have FGFR mutations
The development of best-in-class
FGFR inhibitors effective
for various FGFR-resistant
mutations is highly demanded.
Development of next-generation FGFR inhibitor that can overcome resistance to FGFR kinase inhibitor
- FGFR inhibitor resistant mutation
*FGFR inhibitor market
501.2m USD (2033)
Source : Future Market Insights (2023) Market Report